Core Insights - Anixa Biosciences is reporting promising outcomes from its ongoing Phase 1 clinical trial of CAR-T therapy for recurrent ovarian cancer, with several patients exceeding expected survival rates at low dose levels [1][2][3] Group 1: Trial Overview - The Phase 1 trial is focused on adult women with recurrent ovarian cancer who have not responded to standard chemotherapy and have progressed after two or more therapies [2] - Twelve patients have been treated at four dosage levels, with seven patients living beyond the expected median survival of three to four months [2] - Notably, one patient survived 28 months post-treatment, and three others have survived over one year [2] Group 2: Safety and Efficacy - The trial primarily aims to demonstrate safety, and the absence of dose-limiting toxicities (DLTs) has allowed for significant dose escalation [3][5] - The dosing may increase from 1×10 to as high as 1×10 CAR-positive cells per kilogram, representing a two-order-of-magnitude increase [3] - The favorable safety profile is attributed to the intra-peritoneal delivery method, which may enhance localized tumor targeting while reducing systemic toxicity [3] Group 3: Future Directions - The next patient cohort will receive higher doses following a lymphodepletion regimen, which is expected to create a more favorable environment for CAR-T cell activity [4] - The regulatory approval for the protocol amendment allows for further evaluation of both safety and potential therapeutic benefits as the study progresses [5] - Anixa plans to discuss trial observations and future plans in an upcoming fireside chat on February 10, 2026 [1][6] Group 4: Technology and Collaboration - Anixa's CAR-T therapy, lira-cel, targets the follicle-stimulating hormone receptor (FSHR), which is selectively expressed on ovarian cells and certain cancer cells [7] - The company collaborates with Moffitt Cancer Center, a leader in cancer immunotherapy, to develop its CAR-T therapy and other cancer vaccines [8]

Core Viewpoint - Anixa Biosciences has received approval for the non-proprietary name "liraltagene autoleucel" for its CAR-T therapy targeting recurrent ovarian cancer, marking a significant step towards its commercialization [1][2]. Group 1: Company Developments - The USAN Council approved the non-proprietary name for Anixa's CAR-T therapy, which follows prior approval from the WHO's INN Expert Committee, allowing for a globally recognized drug name [1][2]. - The company is focused on executing its ongoing Phase 1 trial of liraltagene autoleucel, in partnership with Moffitt Cancer Center, aimed at treating ovarian cancer [2][3]. - Liraltagene autoleucel is a novel CAR-T therapy that targets the follicle stimulating hormone receptor (FSHR), which is expressed on normal ovarian cells and certain cancer cells [3]. Group 2: Technology and Research - The CAR-T technology, known as chimeric endocrine receptor-T cell (CER-T) therapy, utilizes a natural ligand to bind to the FSHR receptor on tumor cells, differentiating it from traditional cell therapies [3]. - The ongoing Phase 1 trial is designed to evaluate safety, identify the maximum tolerated dose, and monitor clinical activity in adult women with recurrent ovarian cancer who have progressed after at least two prior therapies [3]. Group 3: Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4]. - The company also has a vaccine portfolio aimed at treating and preventing breast and ovarian cancer, developed in collaboration with Cleveland Clinic, which is entitled to royalties from these technologies [4]. - Anixa's business model involves partnerships with leading research institutions to explore and commercialize emerging technologies in cancer treatment [4].

Core Insights - The article discusses the potential impact of recent economic trends on the investment landscape, highlighting opportunities and challenges for investors [1] Group 1: Economic Trends - Recent economic indicators suggest a shift in market dynamics, with inflation rates showing a significant increase of 5% year-over-year [1] - The unemployment rate has decreased to 4.2%, indicating a tightening labor market that could influence wage growth [1] Group 2: Investment Opportunities - Sectors such as technology and renewable energy are projected to experience substantial growth, with estimates suggesting a market expansion of $500 billion by 2025 [1] - Companies focusing on digital transformation are likely to benefit from increased demand, as businesses adapt to changing consumer behaviors [1] Group 3: Challenges Ahead - Rising interest rates may pose a risk to borrowing costs, potentially slowing down capital investments in various industries [1] - Supply chain disruptions continue to affect manufacturing sectors, leading to increased costs and delays in production [1]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - Aclarion, Inc. (ACON) is up 38% at $7.94 [3] - A SPAC III Acquisition Corp. (ASPC) is up 31% at $21.41 [3] - Nuvve Holding Corp. (NVVE) is up 23% at $4.32 [3] - Acrivon Therapeutics, Inc. (ACRV) is up 20% at $3.55 [3] - PMGC Holdings Inc. (ELAB) is up 16% at $6.76 [3] - Serina Therapeutics, Inc. (SER) is up 14% at $2.73 [3] - Regencell Bioscience Holdings Limited (RGC) is up 13% at $60.00 [3] - One Stop Systems, Inc. (OSS) is up 11% at $8.75 [3] - Anixa Biosciences, Inc. (ANIX) is up 9% at $3.60 [3] - Globus Medical, Inc. (GMED) is up 7% at $96.99 [3] Premarket Losers - Immuneering Corporation (IMRX) is down 23% at $6.34 [4] - Genelux Corporation (GNLX) is down 12% at $2.95 [4] - Erasca, Inc. (ERAS) is down 11% at $4.55 [4] - Phathom Pharmaceuticals, Inc. (PHAT) is down 10% at $16.10 [4] - Acurx Pharmaceuticals, Inc. (ACXP) is down 9% at $2.62 [4] - Evolution Metals & Technologies Corp. (EMAT) is down 8% at $17.34 [4] - Revolution Medicines, Inc. (RVMD) is down 7% at $95.14 [4] - Cardio Diagnostics Holdings, Inc. (CDIO) is down 7% at $2.59 [4] - Vestis Corporation (VSTS) is down 6% at $6.42 [4] - WORK Medical Technology Group LTD (WOK) is down 6% at $2.75 [4]

Core Insights - Anixa Biosciences has received approval from the WHO for the non-proprietary name "liraltagene autoleucel" for its CAR-T therapy targeting recurrent ovarian cancer, marking a significant milestone in its development and potential commercialization [1][2][3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company utilizes a novel CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) therapy, which targets the follicle stimulating hormone receptor (FSHR) expressed on ovarian cells and certain cancer cells [3][4] Clinical Development - The ongoing Phase 1 trial of liraltagene autoleucel is designed to evaluate safety, identify the maximum tolerated dose, and monitor clinical activity in adult women with recurrent ovarian cancer who have progressed after at least two prior therapies [3][4] - The trial is being conducted in partnership with Moffitt Cancer Center, a leader in cancer immunotherapy [2][4] Future Directions - The approval of the non-proprietary name allows Anixa to establish a universally recognized name for its CAR-T therapy, facilitating clearer identification and safe prescription of the drug [2][3] - The company plans to transition to using the name liraltagene autoleucel, or lira-cel, in future communications [2]

Group 1 - Solventum (SOLV) is one of 974 companies in the Medical group, which is currently ranked 7 within the Zacks Sector Rank [2] - Solventum has a Zacks Rank of 1 (Strong Buy), indicating a positive earnings outlook with a 6.1% increase in the consensus estimate for full-year earnings over the past quarter [3] - Year-to-date, Solventum has gained approximately 10.8%, outperforming the Medical sector, which has returned an average of -2.7% [4] Group 2 - Solventum is part of the Medical Services industry, which consists of 58 companies and is currently ranked 99 in the Zacks Industry Rank, with a year-to-date loss of about 2.6% [5] - ANIXA BIOSCIENCES INC (ANIX) is another Medical stock that has outperformed the sector with a return of 51.7% year-to-date and has a Zacks Rank of 2 (Buy) [4][5] - The Medical - Biomedical and Genetics industry, to which ANIX belongs, has a total of 485 stocks and is currently ranked 105, with a year-to-date increase of 2.8% [6]

Company Overview - Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on cancer treatment and prevention [2] - The company has a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) technology [2] - Anixa's vaccine portfolio includes vaccines for breast and ovarian cancer developed in collaboration with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [2] Upcoming Event - Anixa will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 10:30 AM ET [1][2] - The presentation will take place at the Lotte New York Palace Hotel, and Mike Catelani, President and CFO, will be available for one-on-one meetings during the conference [2]

Core Insights - Anixa Biosciences, Inc. will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025, in New York City [1][2] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [2] - The company utilizes a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) technology, which differentiates itself by using the natural ligand of the FSHR receptor, FSH, to bind to tumor cells [2] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [2] - The vaccines are based on immunizing against "retired" proteins expressed in certain cancer forms, with Cleveland Clinic entitled to royalties and commercialization revenues from these technologies [2] - Anixa's business model involves partnerships with renowned research institutions at all development stages, allowing the company to explore emerging technologies for further development and commercialization [2]

Core Insights - Anixa Biosciences is conducting a Phase 1 clinical trial for its CAR-T therapy targeting recurrent ovarian cancer, with the second patient in the fourth dose cohort treated successfully [1][3] - The fourth cohort is receiving a dose of three million CAR-positive cells per kilogram, a 30-fold increase from the initial dose, with no dose-limiting toxicities observed to date [2][4] - The CAR-T program targets the follicle-stimulating hormone receptor (FSHR), which is selectively expressed on ovarian cells and certain cancer cells, indicating a potential for targeted therapy [3][4] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a proprietary CAR-T program developed in collaboration with Moffitt Cancer Center [5] - The CAR-T technology is differentiated by its use of the natural ligand of the FSHR receptor, FSH, which binds directly to tumor cells rather than using an antibody fragment [5] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers, focusing on immunizing against specific proteins expressed in cancer [5]

Core Insights - Anixa Biosciences has received a new patent extending the protection of its CAR-T technology to 2045, enhancing its intellectual property portfolio [1][2][3] - The patent covers fundamental methods and compositions essential to Anixa's CAR-T approach, which aims to tackle challenges in treating solid tumors [2] - Anixa's CAR-T technology is currently in clinical trials for recurrent ovarian cancer at Moffitt Cancer Center, indicating progress in its therapeutic development [2][3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a unique CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) [3] - The company collaborates with leading research institutions, such as Moffitt Cancer Center and Cleveland Clinic, to develop its therapeutic and vaccine portfolios [3] - Anixa's vaccine programs target various cancers, including breast and ovarian cancer, and utilize innovative approaches to immunization [3]